Drug intelligence / Profile preview

iberdomide + polatuzumab vedotin + rituximab

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Oral, Intravenous

Overview

This combination comprises three drugs: **iberdomide** (an oral modulator of cereblon, leading to ubiquitination and degradation of transcription factors Ikaros and Aiolos), **polatuzumab vedotin** (an antibody-drug conjugate targeting CD79b on B-cells, delivering cytotoxic MMAE), and **rituximab** (a monoclonal antibody targeting CD20 on B-cells, mediating cell lysis). The regimen is under clinical evaluation for treatment of **relapsed or refractory aggressive B-cell lymphoma**, specifically diffuse large B-cell lymphoma (DLBCL)[5]. The combination seeks to enhance antitumor response by leveraging complementary mechanisms: direct tumor cell killing (ADC), immune-mediated cytotoxicity (anti-CD20 mAb), and immune modulation (cereblon E3 ligase modulation).

Other names: iberdomideCC-220CC220CC 220polatuzumab vedotinDCDS4501ADCDS-4501ADCDS 4501ArituximabIDEC-C2B8IDEC-C-2B8IDEC-C 2B8anti-CD79b ADCanti-CD-79b ADCanti-CD 79b ADCanti-CD20 monoclonal antibodyanti-CD-20 monoclonal antibodyanti-CD 20 monoclonal antibody

Targets

CRBN (Cereblon)CD20 (B-lymphocyte antigen CD20)B-cell antigen receptor complex-associated protein beta chain

Beyond the preview

Go deeper on iberdomide + polatuzumab vedotin + rituximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iberdomide + polatuzumab vedotin + rituximab.

Explore the full profile